

FOI REF: 25/434

2nd July 2025

Tel: 0300 131 4500
Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

• ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)	2
• Amivantamab	0
• Atezolizumab Monotherapy	10
• Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel	6
• Atezolizumab subcutaneous	0
• Dabrafenib + Trametinib	1
• Docetaxel monotherapy or in combination with Carboplatin/Cisplatin	1
• Durvalumab	1
• Gemcitabine	0
• Nintedanib + Docetaxel	1
• Nivolumab	0
• Osimertinib	27
• Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)	1
• Paclitaxel	0
• Pembrolizumab Monotherapy	15
• Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)	21
• Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)	6
• Pemetrexed + Platinum (Carboplatin/Cisplatin)	3
• RET Inhibitors (Pralsetinib, Selpercatinib)	0
• Sotorasib	0
• Tepotinib	2
• Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin	6
• Other active systemic anti-cancer therapy	13

Cont.../

- **Palliative care only**

Section 12 (1) applied.

East Sussex Healthcare NHS Trust does not centrally record patients being treated for palliative care only. To enable the Trust to provide this information will require a manual review of patients' notes to establish if we hold this information, and discussing each patient with individual clinicians, which we estimate would take in excess of 18 hours. We are therefore applying Section 12(1) to this part of your request.

Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the 'appropriate limit', as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this request would significantly exceed the above limit.

- **Amivantamab with carboplatin and pemetrexed** 0
- **Cemiplimab with platinum-based chemotherapy** 0

Q2. Does your trust participate in any Clinical trials for Non-Small Cell Lung Cancer?

If so, please provide the name of each trial, and the number of patients taking part.

The Trust currently has one lung cancer trial open to recruitment:

'REFINE Lung trial – A randomised open-label phase III trial of reduced frequency pembrolizumab immunotherapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design.'

The Trust has not recruited any patients to date.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department
esh-tr.foi@nhs.net